memantine has been researched along with Psychoses in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports." | 8.93 | Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016) |
| "We sought to determine whether the extended MAPT haplotype was associated with the worsening of delusions and hallucinations in a combined cohort of 95 patients who participated in 2 clinical trials of treatment with memantine." | 5.19 | Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease. ( Ballard, C; Corbett, A; Creese, B; Fox, C; Jones, E, 2014) |
| "Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports." | 4.93 | Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016) |
| "Although Parkinson's disease (PD) has been considered to primarily affect motor abilities, increasing emphasis is being placed on cognitive and behavioural impairment in this disorder." | 2.44 | Cognitive and behavioural impairment in Parkinson's disease. ( Freedman, M; Merims, D, 2008) |
| "Studies have shown that psychosis in Parkinson's disease patients is a strong risk factor for nursing home placement." | 2.44 | Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? ( Fernandez, HH; Zahodne, LB, 2008) |
| "Ketamine has also been observed to exacerbate psychotic symptoms in schizophrenia patients." | 1.39 | Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Marmo, F; Sarappa, C; Tomasetti, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, TW | 1 |
| Chu, CS | 1 |
| Ching, PY | 1 |
| Chen, GW | 1 |
| Pan, CC | 1 |
| Siao, WH | 1 |
| Chang, FY | 1 |
| Chen, YC | 1 |
| Light, GA | 3 |
| Zhang, W | 1 |
| Joshi, YB | 1 |
| Bhakta, S | 2 |
| Talledo, JA | 3 |
| Swerdlow, NR | 3 |
| de Bartolomeis, A | 1 |
| Sarappa, C | 1 |
| Buonaguro, EF | 1 |
| Marmo, F | 1 |
| Eramo, A | 1 |
| Tomasetti, C | 1 |
| Iasevoli, F | 1 |
| Creese, B | 1 |
| Corbett, A | 1 |
| Jones, E | 1 |
| Fox, C | 1 |
| Ballard, C | 1 |
| Chou, HH | 2 |
| Balvaneda, B | 2 |
| Veronese, N | 1 |
| Solmi, M | 1 |
| Luchini, C | 1 |
| Lu, RB | 1 |
| Stubbs, B | 1 |
| Zaninotto, L | 1 |
| Correll, CU | 1 |
| Bhakta, SG | 1 |
| Rana, B | 1 |
| Gaddis, L | 1 |
| Merims, D | 1 |
| Freedman, M | 1 |
| Kyomen, HH | 1 |
| Whitfield, TH | 1 |
| Schmidt, R | 1 |
| Baumhackl, U | 1 |
| Berek, K | 1 |
| Brücke, T | 1 |
| Kapeller, P | 1 |
| Lechner, A | 1 |
| Rainer, M | 1 |
| Stögerer, EM | 1 |
| Osborn, GG | 1 |
| Saunders, AV | 1 |
| Fusar-Poli, P | 1 |
| Pellegrini, F | 1 |
| Cortesi, M | 1 |
| Zahodne, LB | 1 |
| Fernandez, HH | 1 |
| Tariot, PN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
5 reviews available for memantine and Psychoses
| Article | Year |
|---|---|
The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: A systematic review and updated meta-analysis of double-blind randomized controlled trials.
Topics: Antidepressive Agents; Depression; Humans; Memantine; Psychotic Disorders; Randomized Controlled Tri | 2022 |
Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions.
Topics: Adult; Bipolar Disorder; Case-Control Studies; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2016 |
Cognitive and behavioural impairment in Parkinson's disease.
Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Humans; Incidence; Lewy Bo | 2008 |
Current treatments for patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory A | 2010 |
Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?
Topics: Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Dis | 2008 |
4 trials available for memantine and Psychoses
| Article | Year |
|---|---|
Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
Topics: Adult; Antipsychotic Agents; Auditory Perception; Chronic Disease; Cortical Synchronization; Cross-O | 2017 |
Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease.
Topics: Aged; Alleles; Alzheimer Disease; Antipsychotic Agents; Delusions; Disease Progression; Excitatory A | 2014 |
Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy.
Topics: Adult; Biomedical Research; Cognition; Consensus; Cross-Over Studies; Double-Blind Method; Excitator | 2016 |
[Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Austria; Ca | 2010 |
6 other studies available for memantine and Psychoses
| Article | Year |
|---|---|
Memantine treats psychosis and agitation associated with Moderna COVID-19 vaccine.
Topics: 2019-nCoV Vaccine mRNA-1273; Anxiety; COVID-19; Humans; Memantine; Psychotic Disorders | 2023 |
Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis.
Topics: Animals; Antipsychotic Agents; Carrier Proteins; Disks Large Homolog 4 Protein; Dizocilpine Maleate; | 2013 |
Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Habituatio | 2016 |
Psychosis in the elderly.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents | 2009 |
Memantine as a neuroprotective agent in early phases of psychosis.
Topics: Excitatory Amino Acid Antagonists; Humans; Memantine; Neuroprotective Agents; Psychotic Disorders; R | 2007 |
Psychosis and agitation in dementia: should general psychiatrists care?
Topics: Aged; Alzheimer Disease; Dementia; Excitatory Amino Acid Antagonists; Humans; Memantine; Psychotic D | 2008 |